1. Reliability of monitoring the clinical dementia rating in multicenter clinical trials.

    Alzheimer Disease and Associated Disorders 18(4):219 (2004) PMID 15592134

    The Clinical Dementia Rating (CDR) is quickly becoming a criterion standard in multicenter clinical trials in Alzheimer disease. An abbreviated version, with formal monitoring for consistency across sites and raters, is currently used in the Alzheimer's Disease Cooperative Study (ADCS). To demon...
  2. Reliability of monitoring the clinical dementia rating in multicenter clinical trials.

    Alzheimer Disease and Associated Disorders 18(4):219 (2004) PMID 15592134

    The Clinical Dementia Rating (CDR) is quickly becoming a criterion standard in multicenter clinical trials in Alzheimer disease. An abbreviated version, with formal monitoring for consistency across sites and raters, is currently used in the Alzheimer's Disease Cooperative Study (ADCS). To demon...
  3. Reliability of monitoring the clinical dementia rating in multicenter clinical trials.

    Alzheimer Disease and Associated Disorders 18(4):219 (2004) PMID 15592134 PMCID PMC4367865

    The Clinical Dementia Rating (CDR) is quickly becoming a criterion standard in multicenter clinical trials in Alzheimer disease. An abbreviated version, with formal monitoring for consistency across sites and raters, is currently used in the Alzheimer's Disease Cooperative Study (ADCS). To demon...
  4. Reliability of monitoring the clinical dementia rating in multicenter clinical trials.

    Alzheimer Disease and Associated Disorders 18(4):219 (2004) PMID 15592134

    The Clinical Dementia Rating (CDR) is quickly becoming a criterion standard in multicenter clinical trials in Alzheimer disease. An abbreviated version, with formal monitoring for consistency across sites and raters, is currently used in the Alzheimer's Disease Cooperative Study (ADCS). To demon...
  5. Reliability of monitoring the clinical dementia rating in multicenter clinical trials.

    Alzheimer Disease and Associated Disorders 18(4):219 (2004) PMID 15592134

    The Clinical Dementia Rating (CDR) is quickly becoming a criterion standard in multicenter clinical trials in Alzheimer disease. An abbreviated version, with formal monitoring for consistency across sites and raters, is currently used in the Alzheimer's Disease Cooperative Study (ADCS). To demon...
  6. Reliability of monitoring the clinical dementia rating in multicenter clinical trials.

    Alzheimer Disease and Associated Disorders 18(4):219 (2004) PMID 15592134 PMCID PMC4367865

    The Clinical Dementia Rating (CDR) is quickly becoming a criterion standard in multicenter clinical trials in Alzheimer disease. An abbreviated version, with formal monitoring for consistency across sites and raters, is currently used in the Alzheimer's Disease Cooperative Study (ADCS). To demon...
  7. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.

    JAMA 289(21):2819 (2003) PMID 12783912

    Laboratory evidence that inflammatory mechanisms contribute to neuronal injury in Alzheimer disease (AD), along with epidemiological evidence, suggests that nonsteroidal anti-inflammatory drugs (NSAIDs) may favorably influence the course of the disease. To determine whether treatment with a sele...
  8. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.

    JAMA 289(21):2819 (2003) PMID 12783912

    Laboratory evidence that inflammatory mechanisms contribute to neuronal injury in Alzheimer disease (AD), along with epidemiological evidence, suggests that nonsteroidal anti-inflammatory drugs (NSAIDs) may favorably influence the course of the disease. To determine whether treatment with a sele...